Ongoing Clinical Trials

FOCUS Phase 3 Clinical Trial and Pivotal ICC Trial

Clinical Trials

As part of its mission to make a clinically meaningful difference for patients with cancers of the liver, Delcath Systems is deeply committed to the clinical development of Percutaneous Hepatic Perfusion (PHP®)*. To date, PHP has been the subject of peer-reviewed papers, as well as multiple oral and poster presentations. Additional trials are underway to examine the use of PHP in metastatic ocular melanoma, as well as primary liver cancer (HCC/ICC).

* For Investigational Use Only in the U.S.

Learn More>>>


Pill Graphic

Clinical Bibliography

Browse through our online library of published articles and abstracts.

Start Now


Disclaimer:

Delcath does not make any claim whatsoever, real or implied, about the efficacy or safety of any therapy, drug, system, or technique under active research.